Cellectis gene editing patent upheld in Europe

In response to a challenge (opposition procedure), the European Patent Office has upheld the validity of Cellectis' (NASDAQ:CLLS) European Patent EP3004337 covering a method of preparing T cells for immunotherapy using the CRISPR/Cas9 gene editing technology.